Check 35,000+ stocks against 26 valuation models and 37 quality factors

Simcere Pharmaceutical Group Ltd (2096) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Simcere Pharmaceutical Group Ltd HK$13.04, price HK$11.85, upside +10.0%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN HK0000658531

Broad data Oct 1, 2026

Simcere Pharmaceutical Group Ltd

2096 · HK

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value HK$13.04 · Fairly valued (+10.0%)

✓Quality 69/100

!Mixed Growth (revenue 5y +11.4 %/yr)

✓Solidly profitable · 18.0% net margin (TTM)

✓Low debt · generates free cash flow

✓1.5% dividend yield · Well covered

✓Ranks above peers (10/14)

✓Wide moat 70/100

26 models, one by oneBear HK$8.68 to bull HK$17.18 Growth analysisrevenue history, year by year Quality 69/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Simcere Pharmaceutical Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range HK$4.70 – HK$14.49 · fair‑value band HK$8.68 – HK$17.18 · the HK$11.85 price screens below the HK$13.04 fair value. Dashed = 300-day average. As of Oct 1, 2026.

Follow Simcere Pharmaceutical Group in your weekly email

Every Wednesday you see whether Simcere Pharmaceutical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials. It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein; Enzeshu, a suvemcitug for injection; SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3; SIM0508, a small molecule inhibitor; SIM0505, a CDH6-targeting ADC molecule; SIM0686, an ADC drug targeting FGFR2b; SIM0609, a new antibody-drug conjugate targeting CDH17; SIM0610, a bispecific antibody-drug conjugate; SIM0532, an oral, non-covalent pan-RAS inhibitor; SIM0323; and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial. The company develops SIM0613; SIM0709; SIM0689; SIM0688; SIM0518; SIM0616; SIM0611; SIM0815; SIM0712; SIM0725; SIM0708; SIM0721; and SIM0722 that are in pre-clinical stage. It offers pharmaceutical ingredients; production support facility; consulting and technology; promotion; and property management. The company was founded in 1995 and is headquartered in Nanjing, China.

Stock analysis

Simcere Pharmaceutical Group Ltd (2096) currently trades at HK$11.85, while our model-based Fair Value estimate is HK$13.04, implying the stock looks roughly 9.1% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$12.64 per share, and 13 of the 26 models we run sit above the HK$11.85 price.

Bear case: the Dividend Discount group reads lowest at HK$2.69, and 13 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: HK$8.68 (bear) to HK$17.18 (bull), the price of HK$11.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Simcere Pharmaceutical Group Ltd reported revenue of 7.7B CNY in FY2025 versus 5.0B CNY in FY2021, a compound +11.5%/yr. Reported net income was 1.3B CNY in FY2025, compounding −2.8%/yr from FY2021.

Key figures

Market cap HK$30.3B (≈ $3.9B) · P/E ratio 15.8 · P/S ratio 2.74 · Dividend yield 1.5% · Net margin 17.4% · Return on equity 18.8% · Return on assets (EBIT) 9.3% · Operating margin 22.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 10%, 2096 screens cheaper than that median.

Fair Value models

Bear HK$8.68 Fair Value HK$13.04 Bull HK$17.18

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$8.20 HK$12.64 HK$19.71 79

Growth DCF HK$8.19 HK$12.35 HK$18.79 78

Owner Earnings HK$6.66 HK$10.06 HK$15.49 76

All 26 models by family

DCF Models

FCF DCF HK$8.20 HK$12.64 HK$19.71 79

Owner Earnings HK$6.66 HK$10.06 HK$15.49 76

5Y Revenue Exit HK$8.00 HK$12.44 HK$18.32 72

5Y EBITDA Exit HK$9.40 HK$15.23 HK$22.36 74

5Y P/E Exit HK$9.90 HK$16.22 HK$23.25 70

10Y Revenue Exit HK$7.80 HK$11.92 HK$17.93 66

10Y EBITDA Exit HK$8.90 HK$13.88 HK$21.12 67

10Y P/E Exit HK$9.22 HK$14.58 HK$21.83 63

Earnings-Based

Graham-Dodd HK$4.17 HK$16.99 HK$23.13 64

Lynch FV HK$4.26 HK$6.08 HK$7.91 61

PEG = 1.0 HK$4.26 HK$6.08 HK$7.91 57

EPV HK$7.35 HK$8.26 HK$9.04 74

Dividend Discount

Gordon GGM HK$1.56 HK$3.12 HK$4.72 67

DDM Multi-Stage HK$1.56 HK$2.69 HK$3.29 67

Multiples

P/E Multiple HK$10.11 HK$13.48 HK$16.85 63

P/S Multiple HK$7.81 HK$10.41 HK$13.02 58

P/B Multiple HK$7.81 HK$10.41 HK$13.02 55

EV/EBIT HK$10.65 HK$13.67 HK$16.68 66

EV/EBITDA HK$10.88 HK$13.97 HK$17.06 67

EV/Revenue HK$8.07 HK$10.83 HK$13.60 54

Asset-Based

NCAV (Graham) HK$2.15 HK$2.87 HK$4.29 54

Growth DCF

Growth DCF HK$8.19 HK$12.35 HK$18.79 78

Rev-Margin DCF HK$8.00 HK$12.36 HK$17.78 72

Economic Profit

Residual Income HK$4.15 HK$5.23 HK$7.75 75

ROIC Compounder HK$7.98 HK$9.85 HK$12.13 72

Growth Earnings

Growth-Adj P/E HK$7.59 HK$10.84 HK$14.09 67

Open the full fair value analysis →

Notify me when 2096 reaches fair value

Put 2096 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 69/100

Of which business quality 68 · Market factors (momentum, volatility) 45

Profitability 60

Margins and returns on capital today

Quality Growth 61

Are margins and returns improving?

Cashflow 65

Earnings quality: real cash, not paper profit

Fin. Strength 95

Balance sheet, leverage, solvency risk

Investment 49

Disciplined investing over empire-building

Low Volatility 61

Calm price path (market factor)

Momentum 37

Price trend over the last 3–12 months (market factor)

52W Momentum 43

Distance to the 52-week high (market factor)

Net Issuance 71

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 86/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+16.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+11.4%

Start year 2020 (pandemic)

Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+10.6%

’12

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+4.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+3.2%

Dividend (yield on the price)1.5%

Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 20%

2025 sits 86% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

Price in line with expectations

The price assumes about as much growth as the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+9.4%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +7.6% a year for the price.

Watch 2096, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (59 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype

Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development Yahoo Finance · Sep 1, 2026
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients wi Yahoo Finance · Jun 12, 2026
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers Yahoo Finance · May 4, 2026
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 Yahoo Finance · Apr 21, 2026

Compare Simcere Pharmaceutical Group Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 619 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 69 · Top 25%

Fair Value upside +10.0% · Above median

Profitability

Return on equity (TTM) 18.8% · Top 25%

Return on assets 7.8% · Top 25%

Net margin (TTM) 18.0% · Top 25%

Operating margin (TTM) 22.8% · Top 25%

Growth and dividend

Revenue growth 27.8% · Top 25%

Dividend yield (TTM) 1.5% · Below median

Balance sheet

Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 15.8× · Cheaper than median

P/B 2.75× · Pricier than median

P/S (TTM) 2.96× · Pricier than median

P/FCF 22.5× · Pricier than median

EV/EBITDA 10.7× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)47 · sector 14

FUTURE (revenue growth)100 · sector 21

PAST (return on equity)75 · sector 26

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)30 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€135.00	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.19	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Simcere Pharmaceutical Group Ltd · Fair Value
HK$13.04 +9%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/2096" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Simcere Pharmaceutical Group Ltd · Fair Value</span><br><b style="font-size:20px">HK$13.04</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+9%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Simcere Pharmaceutical Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2096

Frequently asked questions

Is Simcere Pharmaceutical Group Ltd (2096) overvalued or undervalued?

As of Oct 1, 2026, our model estimates a fair value of HK$13.04 versus a price of HK$11.85, about +10% upside (undervalued).

What is the fair value of 2096?

Our model-based fair value for Simcere Pharmaceutical Group Ltd is HK$13.04 (as of Oct 1, 2026), built from audited fundamentals. The current price: HK$11.85.

What is the quality score of 2096?

Simcere Pharmaceutical Group Ltd has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Simcere Pharmaceutical Group Ltd (2096)?

Our model-based price target is the fair value of HK$13.04 (as of Oct 1, 2026) from 26 valuation models. Cautious scenario HK$8.68, optimistic scenario HK$17.18. It is a calculation from audited fundamentals, not an analyst target.

What is the Simcere Pharmaceutical Group Ltd stock forecast for 2026?

Our models put fair value at HK$13.04, about +10% upside versus a price of HK$11.85 (undervalued). Cautious scenario HK$8.68, optimistic scenario HK$17.18. The calculation is refreshed regularly with new filings.

What is the revenue of Simcere Pharmaceutical Group Ltd (2096)?

Simcere Pharmaceutical Group Ltd reported trailing-twelve-month revenue of about 8.7B CNY (latest available figure, as of Oct 1, 2026).

Does Simcere Pharmaceutical Group Ltd pay a dividend?

Simcere Pharmaceutical Group Ltd currently shows a dividend yield of about 1.52% relative to its recent price (as of Oct 1, 2026).

What growth is priced into Simcere Pharmaceutical Group Ltd (2096)?

For today's price to be fair in a discounted-cash-flow model, Simcere Pharmaceutical Group Ltd would have to grow free cash flow by +9.4 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.4 % per year. As of Oct 1, 2026.

What discount rate (WACC) does the fair value of 2096 use?

Our models discount Simcere Pharmaceutical Group Ltd at 9.6 %: a base by market capitalisation (mid), damped by beta 0.72, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Simcere Pharmaceutical Group Ltd that is +9.4 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.

How much growth has Simcere Pharmaceutical Group Ltd (2096) delivered so far?

Over the past 5 years revenue at Simcere Pharmaceutical Group Ltd grew +11.4 % a year. The price currently implies +9.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Simcere Pharmaceutical Group Ltd (2096) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Simcere Pharmaceutical Group Ltd (+9.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Simcere Pharmaceutical Group Ltd (2096)?

The free-cash-flow yield on the price is 4.44 %: that much free cash flow Simcere Pharmaceutical Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Simcere Pharmaceutical Group Ltd (2096)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Simcere Pharmaceutical Group Ltd it is HK$13.04 per share (as of Oct 1, 2026), against a price of HK$11.85. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Simcere Pharmaceutical Group Ltd stock overvalued or undervalued in 2026?

As of Oct 1, 2026, 2096 trades below its calculated fair value: price HK$11.85, fair value HK$13.04, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 2096?

No. The price is what the market pays today (HK$11.85); the fair value is what the company's own numbers justify (HK$13.04). For Simcere Pharmaceutical Group Ltd the two are HK$1.19 per share apart. That gap is exactly why we show both numbers side by side.

How much is Simcere Pharmaceutical Group Ltd worth?

The market values Simcere Pharmaceutical Group Ltd at about HK$30.3B (market capitalisation, as of Oct 1, 2026). Per share that is HK$11.85; our models calculate a fair value of HK$13.04 per share.

What do the bullish and bearish scenarios say about 2096?

Our models span a range for Simcere Pharmaceutical Group Ltd: cautious scenario HK$8.68, base HK$13.04, optimistic HK$17.18 per share (as of Oct 1, 2026, price HK$11.85). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 2096?

Simcere Pharmaceutical Group Ltd trades at a price-to-earnings ratio of 15.8 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$13.04 is built from several models across several years. Other multiples: P/B 2.8, P/S 3.0, EV/EBITDA 10.7.

How solid is the balance sheet of Simcere Pharmaceutical Group Ltd (2096)?

Balance-sheet figures for Simcere Pharmaceutical Group Ltd (as of Oct 1, 2026): return on equity 18.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.

How far is 2096 from its 52-week high?

Simcere Pharmaceutical Group Ltd trades at HK$11.85, about 14% below its 52-week high of HK$13.73 and 28% above the low of HK$9.25 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$13.04 is for.

Which stocks are comparable to Simcere Pharmaceutical Group Ltd?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Simcere Pharmaceutical Group Ltd stock attractive at the current price?

The data as of Oct 1, 2026: price HK$11.85, calculated fair value HK$13.04 (+10%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 2096 calculated?

We run Simcere Pharmaceutical Group Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$13.04, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. Simcere Pharmaceutical Group Ltd currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Simcere Pharmaceutical Group Ltd (2096)?

The closing price on Sep 30, 2026 was HK$11.85. Our model-based fair value is HK$13.04, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Simcere Pharmaceutical Group Ltd right now?

A fairly wide model range (HK$8.68 to HK$17.18) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Simcere Pharmaceutical Group Ltd

How large is the market capitalisation of Simcere Pharmaceutical Group Ltd (2096)?

The market capitalisation of Simcere Pharmaceutical Group Ltd is HK$30.3B (≈ $3.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Simcere Pharmaceutical Group Ltd (2096)?

The price-to-sales ratio of Simcere Pharmaceutical Group Ltd is 2.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the dividend yield of Simcere Pharmaceutical Group Ltd (2096)?

The dividend yield of Simcere Pharmaceutical Group Ltd is 1.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Simcere Pharmaceutical Group Ltd (2096)?

The net margin of Simcere Pharmaceutical Group Ltd is 17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Simcere Pharmaceutical Group Ltd (2096)?

The return on equity (ROE) of Simcere Pharmaceutical Group Ltd is 18.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Simcere Pharmaceutical Group Ltd (2096)?

On an EBIT basis the return on assets of Simcere Pharmaceutical Group Ltd is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Simcere Pharmaceutical Group Ltd (2096)?

The operating margin of Simcere Pharmaceutical Group Ltd is 22.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Simcere Pharmaceutical Group Ltd (2096)?

Revenue at Simcere Pharmaceutical Group Ltd is growing +27.8% versus a year earlier (3y avg +7.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Simcere Pharmaceutical Group Ltd (2096)?

Earnings per share at Simcere Pharmaceutical Group Ltd are growing +30.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Simcere Pharmaceutical Group Ltd (2096) hold?

Simcere Pharmaceutical Group Ltd holds more cash than debt, 2.4B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Simcere Pharmaceutical Group Ltd in the live analysis

One click puts Simcere Pharmaceutical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.